Angelica Therapeutics Receives a $244,479 Qualified Therapeutic Discovery Project Grant for Its Anti-C... ( EMERYVILLE Calif. Dec. 9 2010 /- Ange...)

Angelica Therapeutics Receives a $244,479 Qualified Therapeutic Discovery Project Grant for Its Anti-Cancer Drug

Date:12/9/2010

EMERYVILLE, Calif., Dec. 9, 2010 /PRNewswire/ -- Angelica Therapeutics, Inc., a privately held drug development company focused on the development and commercialization of therapeutics incorporating novel nonimmunogenic fusion toxins, announced that it has received a $244,479 grant under the IRS Qualified Therapeutic Discovery Project Program. The grant is to advance the development of Angelica's lead drug candidate, Angeloxin, a fusion toxin consisting of deimmunized Diphtheria toxin (DT) fused to Interleukin-2 (IL2).

The Qualified Therapeutic Discovery Project Program was part of the healthcare reform legislation enacted in March of this year and established a one-time pool of $1 billion for grants to small biotech companies developing novel therapeutics which show potential to, among other things, result in new therapies that either treat areas of unmet medical need, or prevent, detect, or treat chronic or acute diseases and conditions or significantly advance the goal of curing cancer.

Angelica has collaborated with Antitope, Ltd. (Cambridge, UK) to remove the T cell epitopes from Diphtheria toxin while retaining its cytotoxic potency. Angeloxin, currently in preclinical development, is the most advanced drug candidate derived from Angelica's technology platform. It promises to be an advance over Ontak®, currently marketed for the treatment of cutaneous T cell lymphoma and with reports of efficacy in other cancers as well, including peripheral T cell lymphoma and melanoma.

Geoff Davis, CEO of Angelica, said, "We are very pleased to see Angeloxin and the underlying technology platform recognized by this award. We anticipate that our technology will constitute a significant advance in enabling repeated administration of highly potent and targeted drugs, even to immunocompetent patients, primarily for the treatment of cancer."

About Angelica Therapeutics, Inc. (

SOURCE Angelica Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine technology :

1. Talecris Biotherapeutics Enrolls Patients in Clinical Trial Evaluating Two Doses of PROLASTIN®-C
2. Osseon® Therapeutics Names Gary Coughlen, CPA as New Chief Financial Officer
3. Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinsons Disease
4. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
5. Nile Therapeutics Receives NASDAQ Notice; Will Request Hearing
6. Halozyme Therapeutics Realigns Management
7. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
8. The European Medicines Agency Validates and Accepts Cell Therapeutics Marketing Authorization Application for Pixuvri™
9. Nile Therapeutics Reports 2010 Third Quarter Financial Results
10. Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
11. ImmunGenes Pipeline of Next Generation Cancer Therapeutics Featured in BioWorld Today

Post Your Comments:

(Date:5/18/2013)... 2013 The Open Paradigm Project, in ... Occupy Psychiatry , and leading organizations in the ... social media campaign showcasing video testimonials by individuals ... focuses on pathology and illness rather than wellness ... Psychiatric Association,s (APA) rollout of its latest revision ...

(Date:5/17/2013)... -- Medical devices are any medical items that are ... of their different mechanisms, actions and regulatory requirements, medical ... drug trails due to their unique clinical practices. Currently, ... both safety and efficacy (which is left to the ... as the SFDA) evaluate MDs for both safety and ...

(Date:5/17/2013)... , May 17, 2013 Orexigen® Therapeutics, Inc. (Nasdaq: ... a company overview at the UBS Global Healthcare Conference in ... for Wednesday, May 22 nd at 11 a.m. Eastern ... of the presentation, please visit the Investor Relations section of ... will be available for 14 days after the event. ...

Breaking Medicine Technology:New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2 New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3 Statistical Challenges in Medical Device Trail Evaluation 2

[0] New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses [0] Statistical Challenges in Medical Device Trail Evaluation [0] Orexigen Therapeutics to Present at the UBS Global Healthcare Conference

... ImpactRx, the pioneer in measuring the impact of ... of POP 2.0, a proprietary, event-triggered survey tool ... Triggered by events already collected through ... surveys enable ImpactRx to uniquely capture an understanding ...

... Shire plc (LSE: SHP, NASDAQ: SHPGY ... will join the Board of Directors on September 1 st ... a member of the Company,s Audit, Compliance & Risk Committee. ... David Stout will join the Nomination Committee and Remuneration Committee ...

Cached Medicine Technology:Enhanced POP 2.0 Provides Custom Insight Into the Physician's Mindset at the Point of Promotion and Prescribing 2 Shire plc: Board Changes 2 Shire plc: Board Changes 3

Enhanced POP 2.0 Provides Custom Insight Into the Physician's Mindset at the Point of Promotion and Prescribing Shire plc: Board Changes

(Date:5/20/2013)... (PRWEB) May 20, 2013 iGearUnlimited.com asked schools' ... iPad case for students. The answers didn't surprise anyone: , ... daily use and abuse, 2. Not too bulky – need ... backpack, 3. Built-in kick-stand that works in both vertical and ... as a trackable barcodes on each case, 5. Customizable – ...

(Date:5/20/2013)... Atlanta, GA (PRWEB) May 20, 2013 ... opening of their newest office on Briarcliff Road in ... urgent care facility includes Dr. Fidias E. De ... massage therapists who will provide extensive medical services, occupational ... of the greater Atlanta metropolitan area. They also offer ...

(Date:5/20/2013)... OH (PRWEB) May 20, 2013 The ... experienced medical device law firm, report that two important ... coming months in state and federal litigations established for ... June 11th, the first C.R. Bard bellwether trial will ... Southern District of West Virginia. (In re: C.R. ...

(Date:5/19/2013)... NY (PRWEB) May 20, 2013 Alonso ... they are representing a New York woman in a ... with the National Football League (NFL). According to an ... Petitioner is seeking a declaration of paternity, order of support ... of her son with Mr. Walker. (Docket No. P-18821-13) ...

(Date:5/19/2013)... measure of the heterogeneity the variety of genetic mutations ... outcomes of patients with the most common type of head ... the journal Cancer , investigators at Massachusetts General Hospital ... measure was a better predictor of survival than most traditional ... cell carcinoma of the head and neck. , ...

Breaking Medicine News(10 mins):Health News:New Rugged iPad Case for Bretford Charging Cart Saves the Day for School Deployments 2 Health News:New Rugged iPad Case for Bretford Charging Cart Saves the Day for School Deployments 3 Health News:Healing Heart Urgent Care Opens New Office In Atlanta 2 Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 2 Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 3 Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 4 Health News:New York Woman in Paternity Petition Against Former NFL Running Back, Herschel Walker, Alonso Krangle LLP Representing Petitioner 2 Health News:New York Woman in Paternity Petition Against Former NFL Running Back, Herschel Walker, Alonso Krangle LLP Representing Petitioner 3 Health News:Genetic diversity within tumors predicts outcome in head and neck cancer 2 Health News:Genetic diversity within tumors predicts outcome in head and neck cancer 3

[0] New Rugged iPad Case for Bretford Charging Cart Saves the Day for School Deployments [0] Healing Heart Urgent Care Opens New Office In Atlanta [0] Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials [0] New York Woman in Paternity Petition Against Former NFL Running Back, Herschel Walker, Alonso Krangle LLP Representing Petitioner [0] Genetic diversity within tumors predicts outcome in head and neck cancer

... 91% Increase in Earnings for First Half of 2008 ... Metropolitan,Health Networks, Inc. (Amex: MDF ), a ... results for the six months,and quarter ended June 30, ... that in the three months ended,June 30, 2008, the ...

... /Xinhua-PRNewswire/ -- Simcere Pharmaceutical,Group (NYSE: SCR ), a ... of the patented anti-cancer biotech,product Endu in China, today ... 2008., Highlights -- Total revenue increased ... second quarter, representing a 30.4% year-over-year growth;, ...

... Year-over-Year to $10.7 Million Backlog Reaches $72 ... Million ... to Market Recently-introduced Odyssey System Building Strong Market Momentum, ST. ... second quarter ended June,30, 2008. Revenue for the recent second quarter increased 36% ...

... goes for gold and aims to give back to Mercy Ships ... ... Laser Champion and one of Britain,s greatest medal hopes at the Beijing ... charity Mercy Ships which provides free medical care to the people of ...

... major website re-design, aimed specifically toward potential clients, with improved ... ... New York, NY (PRWEB) August 5, 2008 -- ... re-design, aimed specifically toward potential clients, with improved navigability, clear ...

... esignature, Princor representatives now benefit from a more efficient account ... ... Ontario, CA (PRWEB) August 5, 2008 -- Interlink Electronics, Inc. ... Corporation, a member of the Principal Financial Group®. The Princor® ...

Metropolitan Health Networks Reports 2008 Second Quarter Results Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results Stereotaxis Reports Record Second Quarter Revenue Olympic Sailing Hopeful Backs Hospital Ship Charity Re-Designed Legal Website Includes Blog Interlink and LaserApp Partnership Provides eSignature-Ready Forms to Princor Financial Services

The Easy Wrap Apron is now available with an attached Thyroid Collar. The Thyroid Collar is held on with velcro so it adjusts to fully protect the neck. This Apron with Collar is available in 5mm lea...

... system is a long term, ... clinically proven design. Available in ... correct cruciate retaining configurations. In ... of identification keeps the user ...

... The Genesis II® Total Knee System ... Now, far more is possible with less ... options, while fully addressing both clinical and ... meet these design goals, giving surgeons creative ...

Cementless hip system...

Medicine Products:

Easy Wrap Apron w/Collar: Lead Free Proven™ Posterior Stabilized Knee System Genesis II® Total Knee System Primaloc™ Cementless